Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Compound Heterozygosity of Two Novel JAK2 Mutations in Hereditary Essential Thrombocythemia Implicates Important Monomer-Monomer Interactions in Thrombopoiesis Signaling

Kiersten Ricci, MD, Erika Huber, Ashok Raj, MD, Mohammad Azam, PhD, Theodosia A. Kalfa, MD PhD

Blood (2016) 128 (22): 3137.

https://doi.org/10.1182/blood.V128.22.3137.3137

Published: 2016

Journal Articles

A Multi-Center, Phase-2 Trial of Losartan for the Nephropathy of Sickle Cell Anemia

Charles T. Quinn, MD MS, Santosh L. Saraf, MD, Victor R. Gordeuk, MD, Courtney D. Fitzhugh, MD, Susan E Creary, MD MSc, Prasad Bodas, MD, Alex George, MD, PhD, Ashok Raj, MD, Alecia C. Nero, MD, Catherine Terrell, BS, Lisa McCord, BS, Omar Niss, MD, Rubina Dosani, MS, Michael D. Taylor, MD, Prasad Devarajan, MD, Punam Malik, MD

Blood (2016) 128 (22): 265.

https://doi.org/10.1182/blood.V128.22.265.265

Published: 2016

Journal Articles

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of Romiplostim in Children with Immune Thrombocytopenia (ITP)

Michael D Tarantino, MD, James B. Bussel, Victor S. Blanchette, Jenny Despotovic, Carolyn Bennett, Ashok Raj, MD, Bronwyn Williams, Donald Beam, Jaime Morales, Melissa J. Rose, Nancy Carpenter, Kun Nie, Melissa Eisen

Blood (2015) 126 (23): 7.

https://doi.org/10.1182/blood.V126.23.7.7

Published: 2015

Journal Articles

Reduction in the Frequency of Emergency Department Visits for Complications Related to Sickle Hemoglobinopathies: Effects of Aggressive Hydroxyurea Therapy

Ashok Raj, MD, Arun Ranjan Panigrahi, MD, Scott N. Myers, MD MPH, MSc, Jennifer Mullinax, MD, John A Myers, Pradeep Padmanabhan, MD

Blood (2015) 126 (23): 2067.

https://doi.org/10.1182/blood.V126.23.2067.2067

Published: 2015

Journal Articles

Safety and Efficacy of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Pediatric Patients with Immune Thrombocytopenia (ITP)

Michael D Tarantino, MD, James B. Bussel, MD, Victor S. Blanchette, MD FRCP, Jenny M. Despotovic, DO, MS, Carolyn Bennett, Ashok Raj, MD, Bronwyn Williams, Donald Beam, Jaime Morales, Melissa J. Rose, DO, Kun Nie, Melissa Eisen, MD

Blood (2015) 126 (23): 3467.

https://doi.org/10.1182/blood.V126.23.3467.3467

Published: 2015

Journal Articles

Antibody Development in Pediatric Sickle Cell Patients Undergoing Erythrocytapheresis: A 10 Year Review

William B Lockwood, PhD, MD, Gwendolyn J Godfrey, DO, MPH, Salvatore Bertolone, MD, Ashok Raj, MD

Blood (2008) 112 (11): 3042.

https://doi.org/10.1182/blood.V112.11.3042.3042

Published: 2008

NARROW

Compound Heterozygosity of Two Novel JAK2 Mutations in Hereditary Essential Thrombocythemia Implicates Important Monomer-Monomer Interactions in Thrombopoiesis Signaling

A Multi-Center, Phase-2 Trial of Losartan for the Nephropathy of Sickle Cell Anemia

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of Romiplostim in Children with Immune Thrombocytopenia (ITP)

Reduction in the Frequency of Emergency Department Visits for Complications Related to Sickle Hemoglobinopathies: Effects of Aggressive Hydroxyurea Therapy

Safety and Efficacy of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Pediatric Patients with Immune Thrombocytopenia (ITP)

Antibody Development in Pediatric Sickle Cell Patients Undergoing Erythrocytapheresis: A 10 Year Review

Email alerts

ASH Publications

American Society of Hematology

Compound Heterozygosity of Two Novel JAK2 Mutations in Hereditary Essential Thrombocythemia Implicates Important Monomer-Monomer Interactions in Thrombopoiesis Signaling

A Multi-Center, Phase-2 Trial of Losartan for the Nephropathy of Sickle Cell Anemia

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of Romiplostim in Children with Immune Thrombocytopenia (ITP)

Reduction in the Frequency of Emergency Department Visits for Complications Related to Sickle Hemoglobinopathies: Effects of Aggressive Hydroxyurea Therapy

Safety and Efficacy of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Pediatric Patients with Immune Thrombocytopenia (ITP)

Antibody Development in Pediatric Sickle Cell Patients Undergoing Erythrocytapheresis: A 10 Year Review

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only